Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Part of overall AMCP Nexus page

Program Description

Cardiovascular-kidney-metabolic (CKM) syndrome is a progressive, multi-system condition characterized by the coexistence of chronic kidney disease, metabolic dysfunction, and cardiovascular disease. With overlapping pathophysiology and compounding risks, CKM poses significant challenges in treatment selection, particularly when patients present with both cardiac and renal comorbidities. Sodium glucose cotransporter 2 (SGLT2) inhibitors have emerged as a cornerstone of therapy, demonstrating efficacy across glucose management, cardiovascular outcomes, and renal protection. However, with multiple agents available and variable data across patient populations, selecting the most appropriate treatment can be complex. This discussion will examine the latest clinical data on SGLT2 inhibitors, including their impact on disease progression, hospitalization, and mortality. It will also address the nuances of choosing therapy in patients with overlapping conditions and explore guideline-directed treatment strategies supported by real-world evidence. A case-based discussion will be included to illustrate how pharmacists can evaluate available options and advocate for access to cost-effective, evidence-based care that supports improved patient outcomes and system-wide value.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain cardiovascular-kidney-metabolic (CKM) syndrome and the importance of early identification, diagnosis, and prompt treatment to improve prognosis, including slowing the disease process and reducing complications.
• Apply the guideline recommendations for CKM syndrome, including heart failure and chronic kidney disease, and the data supporting the use of SGLT2 inhibitors in the care of patients with cardiorenal syndrome with or without diabetes.
• Determine an individualized treatment strategy integrating best practices using SGLT2 inhibitors for patients with CKM syndrome to promote quality care while efficiently allocating health care resources.